Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis

The overall survival of patients with lung cancer is dismal despite extensive effort in improvement of diagnosis and treatment. A better understanding of the multistep genetic and epigenetic alterations in lung cancer pathogenesis and progression is necessary for development of improved diagnostic approaches and new targeted therapies. Identification of molecular alterations in the early lung carcinogenesis, together with advanced molecular techniques, may facilitate development of rapid and effective methods for early diagnosis and prognosis of lung carcinoma. In this review, we discuss current understanding of lung carcinogenesis and prospective molecular markers in lung cancer diagnosis. Although the impact of translating new technologies into clinical practice on survival has not been completely determined, they offer a new avenue of exciting novel approaches to early diagnosis of this deadly disease.

[1]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[2]  H. Nakamura,et al.  Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis , 2005, Thorax.

[3]  S. Hirohashi,et al.  Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. , 2005, Lung cancer.

[4]  Shuji Ogino,et al.  Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[5]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[6]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[7]  M. Kris,et al.  Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Suk Woo Nam,et al.  Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.

[9]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Bradley P. Coe,et al.  Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells , 2005, British Journal of Cancer.

[11]  Hiroyuki Sakurai,et al.  Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas , 2005, Cancer.

[12]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[13]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[14]  S. Lam,et al.  Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. , 2005, Human molecular genetics.

[15]  T. Utsunomiya,et al.  Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma , 2005, Clinical Cancer Research.

[16]  E. Cook,et al.  A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. , 2005, Cancer research.

[17]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[18]  G. Bepler,et al.  Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. , 2004, Lung cancer.

[19]  F. Cappuzzo,et al.  Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.

[20]  R. Dziadziuszko,et al.  Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer. , 2004, Anticancer research.

[21]  E. Bowman,et al.  Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. , 2004, Human pathology.

[22]  Y. Tomizawa,et al.  Allelic losses on chromosome 3p are accumulated in relation to morphological changes of lung adenocarcinoma , 2004, British Journal of Cancer.

[23]  Shuta Tomida,et al.  Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients , 2004, Oncogene.

[24]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[25]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[26]  A. Marchetti,et al.  K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. , 2004, Lung cancer.

[27]  C. Moon,et al.  Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer , 2004, Clinical Cancer Research.

[28]  Y. Yatabe,et al.  Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Scagliotti,et al.  Adjuvant chemotherapy after complete resection for early stage NSCLC. , 2003, Lung cancer.

[30]  M. Papotti,et al.  Is high‐grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? , 2003, The Journal of pathology.

[31]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[32]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Yu Shyr,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[34]  Nicole Benoit,et al.  p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. , 2003, Journal of the National Cancer Institute.

[35]  Y. Shim,et al.  Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.

[36]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Michael J Campa,et al.  Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. , 2003, Cancer research.

[38]  E. Cook,et al.  Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[40]  M. Lerman,et al.  Critical tumor‐suppressor gene regions on chromosome 3P in major human epithelial malignancies: Allelotyping and quantitative real‐time PCR , 2002, International journal of cancer.

[41]  R. Weichselbaum,et al.  Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. , 2002, European journal of cancer.

[42]  L. Thiberville,et al.  Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: A prospective study in high‐risk patients without invasive cancer. , 2002, International journal of cancer.

[43]  J. Minna,et al.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  F. Gilliland,et al.  Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.

[45]  J. Avruch,et al.  The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1 , 2002, Oncogene.

[46]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[48]  J. Jett,et al.  Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Minna,et al.  Fragile histidine triad (FHIT) gene abnormalities in lung cancer. , 2000, Clinical lung cancer.

[50]  A. Gemma,et al.  Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[52]  K. Kerr,et al.  The association between atypical adenomatous hyperplasia and primary lung cancer , 2000, British Journal of Cancer.

[53]  J. Minna,et al.  Molecular changes in the bronchial epithelium of patients with small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[55]  D. Flieder,et al.  Small peripheral glandular lesions detected by screening CT for lung cancer. A diagnostic dilemma for the pathologist. , 2000, Radiologic clinics of North America.

[56]  S. Lam,et al.  High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. , 2000, Cancer research.

[57]  J. Minna,et al.  Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features , 2000, British Journal of Cancer.

[58]  E. Mark,et al.  Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. , 1999, Journal of the National Cancer Institute.

[59]  C. Croce,et al.  The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Takaaki Ito,et al.  Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. , 1999, American journal of clinical pathology.

[61]  D. Harpole,et al.  A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. , 1999, The Journal of thoracic and cardiovascular surgery.

[62]  J. Herman,et al.  Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.

[63]  J. Minna,et al.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.

[64]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Samet,et al.  Molecular damage in the bronchial epithelium of current and former smokers. , 1997, Journal of the National Cancer Institute.

[66]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[67]  C. D. Edwards,et al.  Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. , 1995, Cancer research.

[68]  F. Berger,et al.  p53 genetic abnormalities and myc activation in human lung carcinoma , 1994, International journal of cancer.

[69]  R. Hruban,et al.  Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.

[70]  S. Rodenhuis,et al.  K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung , 1993, Cancer.

[71]  M. Weber,et al.  Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.

[72]  K. Kerr,et al.  Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. , 1992, Thorax.

[73]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[74]  S. Rodenhuis,et al.  The ras oncogenes in human lung cancer. , 1990, The American review of respiratory disease.

[75]  Y. Ishikawa,et al.  High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs , 2005, Journal of Cancer Research and Clinical Oncology.

[76]  H. Kato,et al.  K-ras mutation in sputum of primary lung cancer patients does not always reflect that of cancerous cells. , 2001, International journal of oncology.

[77]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Y. Pekarsky,et al.  Role of FHIT in human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Z. Ronai,et al.  K‐ras mutation in sputum of patients with or without lung cancer , 1996, Journal of cellular biochemistry. Supplement.

[80]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.